Chemoprevention of breast cancer

Breast Cancer Research and Treatment

Volumn 62, Issue 1, 2000, Pages 1-17

  Brown, P H ^a   Lippman, S M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Prevention; Raloxifene; Retinoids; SERMs; Tamoxifen

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTINEOPLASTIC AGENT; ARZOXIFENE; CYCLOOXYGENASE 2 INHIBITOR; DROLOXIFENE; EFLORNITHINE; ESTROGEN RECEPTOR; FENRETINIDE; FULVESTRANT; IDOXIFENE; ISOFLAVONE DERIVATIVE; LASOFOXIFENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TERPENE; TOREMIFENE; VITAMIN D DERIVATIVE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CARCINOMA IN SITU; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ETHNIC GROUP; FEMALE; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; ONCOGENE; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR DISEASE;

ADULT; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MASTECTOMY; QUALITY OF LIFE; RALOXIFENE; RISK FACTORS; TAMOXIFEN;

EID: 0033866203     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006484604454     Document Type: Review

References (74)

1. Cancer statistics, 2000
2. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
3. Tamoxifen, raloxifene, and the prevention of breast cancer
4. Antiestrogens-tamoxifen, SERMs and beyond
5. Tamoxifen prevention of breast cancer: An instance of the fingerpost
6. Tamoxifen for early breast cancer: An overview of the randomized trials
7. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
8. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
9. The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): Preliminary results of NSABP protocol B-24
10. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial
11. Cancer chemoprevention: Progress and promise
12. Tamoxifen in the treatment of breast cancer
13. Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow
14. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth
15. Letter: Re: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
16. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
17. Bone mass and the risk of breast cancer among postmenopausal women
18. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study
19. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
20. The protective effects of estrogen on the cardiovascular systems
21. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
22. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
23. Base-line quality of life assessment in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial
24. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
25. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
26. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
27. National surgical adjuvant breast and bowel project breast cancer prevention trial: A reflective commentary
28. Re: Tamoxifen prevention of breast cancer: An instance of the fingerpost [letter]
29. Response: Re: Tamoxifen prevention of breast cancer: An instance of the fingerpost [letter]
30. Response: Re: Tamoxifen prevention of breast cancer: An instance of the fingerpost [letter]
31. Putting the risk of breast cancer in perspective
32. Ductal carcinoma in situ - The focus for prevention, screening, and breast conservation in breast cancer
33. Relation of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the primary tumor
34. Tamoxifen hits the target in situ
35. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
36. Risk/benefit assessment of tamoxifen to prevent breast cancer - Still a work in progress?
37. Response: Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? [letter]
38. Incidence of contralateral breast cancer (CBC), endometrial cancer (EC), and thromboembolic events (TE) in African American (AA) women receiving tamoxifen for treatment of primary breast cancer [abstract]
39. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
40. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
41. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
42. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
43. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
44. Prophylactic mastectomy - The price of fear
45. Pathogenesis of estrogen receptor positive and negative breast cancer
46. BRCA1 inhibition of estrogen receptor signaling in transfected cells
47. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
48. How is tamoxifen's action subverted?
49. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
50. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
51. Raloxifene reduces incident primary breast cancers: Integrated data from multi-center, double-blind, placebo-controlled, randomized trials in postmenopausal women
52. Cancer chemoprevention
53. Chemoprevention of breast cancer
54. A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions
55. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxy-genase 2 inhibitor
56. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells
57. Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different machanisms
58. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
59. Suppression of retinoic acid receptor beta in oral premalignant lesions and its upregulation by isotretinoin
60. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis
61. Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue
62. Cellular retinol-binding protein expression and breast cancer
63. Aberrant retinoid signaling and breast cancer: The view from outside the nucleus
64. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma
65. Effect of the retinoid X receptor-selective ligand LGD 1069 on mammary carcinoma after tamoxifen failure
66. Retinoid X receptor and peroxisome proliferater-activated receptor activate an estrogen responsive gene independent of the estrogen receptor
67. Activation and inhibition of the AP-1 complex in human breast cancer cells
68. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells
69. Induction of retinoid resistance in breast cancer cells by overexpression of cJun
70. RRR-α-tocopheryl succinate induces prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells
71. CJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype
72. Increased activator protein-1 DNA binding and cJun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
73. Tamoxifen-stimulated breast tumor growth in vivo is associated with oxidative stress and increased AP-1 activity
74. Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression